Hepatitis, Toxic

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Hepatitis, Toxic trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 4

NCT06484530

Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis

Tuberculosis (TB) remains a significant public health concern in Thailand and globally, especially in tropical regions, with pulmonary TB being predominant. Bes…

Thailand116 participantsStarted 2024-03-12

Treatment: N acetyl cysteine

All recent trials (14 shown)

UnknownNot Applicable

NCT05563961

A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharma…

To investigate and compare the possible response of Panadol® and SafeTynadol® formulations in healthy volunteers and the safety in SafeTynadol® dose-limiting he…

Taiwan48 participantsStarted 2022-10-28

Treatment: Panadol®, SafeTynadol®

CompletedNot Applicable

NCT03071133

Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving…

An observational, postmarketing commitment following the marketing authorization for DCV Trio therapy in Japan

Japan344 participantsStarted 2018-01-01

Hepatitis, Toxic

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis

All recent trials (14 shown)

A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharma…

Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving…

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis

All recent trials (14 shown)

A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharma…

Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving…

Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.

Monitoring the IMmUological TOXicity of Drugs

An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C

Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection

A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Te…

Cholestatic Drug-induced Liver Injury

Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti…

A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC)

Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity